JP2017508442A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508442A5
JP2017508442A5 JP2016546862A JP2016546862A JP2017508442A5 JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5 JP 2016546862 A JP2016546862 A JP 2016546862A JP 2016546862 A JP2016546862 A JP 2016546862A JP 2017508442 A5 JP2017508442 A5 JP 2017508442A5
Authority
JP
Japan
Prior art keywords
genes listed
derivative
mdm2i
salt
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016546862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017508442A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2015/051157 external-priority patent/WO2015108175A1/en
Publication of JP2017508442A publication Critical patent/JP2017508442A/ja
Publication of JP2017508442A5 publication Critical patent/JP2017508442A5/ja
Pending legal-status Critical Current

Links

JP2016546862A 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー Pending JP2017508442A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461927310P 2014-01-14 2014-01-14
US61/927,310 2014-01-14
PCT/JP2015/051157 WO2015108175A1 (en) 2014-01-14 2015-01-13 Gene signatures associated with sensitivity to mdm2 inhibitors

Publications (2)

Publication Number Publication Date
JP2017508442A JP2017508442A (ja) 2017-03-30
JP2017508442A5 true JP2017508442A5 (enExample) 2018-02-08

Family

ID=52432889

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016546862A Pending JP2017508442A (ja) 2014-01-14 2015-01-13 Mdm2阻害剤に対する感受性と関連する遺伝子シグネチャー

Country Status (4)

Country Link
US (1) US20160333419A1 (enExample)
EP (1) EP3094746A1 (enExample)
JP (1) JP2017508442A (enExample)
WO (1) WO2015108175A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
TWI750129B (zh) * 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之gdf-15
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201517216D0 (en) 2015-09-29 2015-11-11 Cancer Res Technology Ltd And Astex Therapeutics Ltd Pharmaceutical compounds
TWI806822B (zh) * 2015-10-23 2023-07-01 日商第一三共股份有限公司 製備治療癌症之醫藥組成物之用途
HK1253320A1 (zh) 2015-10-23 2019-06-14 Daiichi Sankyo Company, Limited 用於治疗aml的药物组合物和治疗有此需要的对象中的aml的方法
CN106512009B (zh) * 2016-10-28 2019-10-11 武汉大学 Ph同源域家族a成员3(phlda3)在治疗心肌肥厚中的应用
GB201704965D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
GB201704966D0 (en) 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
WO2020235671A1 (ja) * 2019-05-23 2020-11-26 国立大学法人大阪大学 性ホルモン非感受性greb1陽性腫瘍の治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150159222A1 (en) * 2012-07-31 2015-06-11 Novartis Ag Markers associated with human double minute 2 inhibitors
SG11201510816SA (en) * 2013-07-03 2016-01-28 Hoffmann La Roche Mrna-based gene expression for personalizing patient cancer therapy with an mdm2 antagonist

Similar Documents

Publication Publication Date Title
JP2017508442A5 (enExample)
CN112930569B (zh) 无细胞dna中的微卫星不稳定性检测
Ropers On the future of genetic risk assessment
Desai et al. Next‐generation sequencing: ready for the clinics?
Bilke et al. Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer
JP2013127477A5 (enExample)
Vos et al. Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
EP4574992A3 (en) Combinatorial dna screening
JP2017523810A5 (enExample)
Noviello et al. Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial
JP2016532689A5 (enExample)
JP2017512491A5 (enExample)
JP2016000057A5 (enExample)
RU2013158861A (ru) Способы и композиции для предсказания активности модулятора ретиноидного х-рецептора
JP2017532959A5 (enExample)
JP2011528903A5 (enExample)
WO2020081012A1 (en) Method for quantifying molecular activity in cancer cells of a human tumour
JP2017501143A5 (enExample)
JP2017509351A5 (enExample)
Ju et al. Identification of a miRNA-mRNA network associated with lymph node metastasis in colorectal cancer
US20150071946A1 (en) Tumor-specific retrotransposon insertions
KR20170072685A (ko) 삼중음성유방암의 아형 분류 방법
CN111480079A (zh) 疾病蛋白质组蛋白质阵列及其应用
JP2012507291A5 (enExample)
Huang et al. Discovery of somatic mutations in the progression of chronic myeloid leukemia by whole-exome sequencing